BioCentury
ARTICLE | Clinical News

MDX-1097: Phase II ongoing

June 27, 2011 7:00 AM UTC

Immune System Therapeutics said a DSMB recommended enrollment of an additional 14 patients in an open-label, Australian Phase II trial after an interim review showed 1 response in 6 patients, with no ...